Related Experiment Videos
What is the optimal therapy for childhood AML?
David M Loeb1, Robert J Arceci
1Johns Hopkins Oncology Center, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231, USA.
Insights
Intensive therapy improves outcomes for pediatric acute myelogenous leukemia (AML) patients, but cure rates remain around 50%. Future advances in pediatric AML treatment may come from alternative strategies beyond intensified chemotherapy.
Area of Science:
- Pediatric Oncology
- Hematology
- Leukemia Research
Background:
- Intensive therapy has significantly improved outcomes for pediatric acute myelogenous leukemia (AML).
- Despite advances like high-intensity chemotherapy and bone marrow transplantation, cure rates for pediatric AML remain approximately 50%.
- Further increases in chemotherapy intensity are unlikely to yield substantial improvements.
Purpose of the Study:
- To explore alternative therapeutic strategies for improving cure rates in pediatric acute myelogenous leukemia (AML).
- To identify novel approaches beyond conventional intensive chemotherapy for treating pediatric AML.
Main Methods:
- Review of existing studies on intensive therapy for pediatric AML.
- Exploration of alternative treatment modalities including risk-directed therapy, differentiation therapy, and immunotherapy.
Main Results:
- Intensive therapy has demonstrated dramatic improvements in pediatric AML outcomes.
- Current intensive chemotherapy and bone marrow transplantation achieve cure rates of about 50% in children with AML.
Conclusions:
- Future progress in pediatric AML treatment necessitates exploring alternative strategies.
- Promising alternative approaches include risk-directed therapy, differentiation agents (ATRA, arsenic trioxide, azacytidine), and immunotherapy (monoclonal antibodies, vaccines, cytokines).
Abstract:
The use of intensive therapy overa brief period of time has produced dramatic improvements in outcome for pediatric patients with acute myelogenous leukemia (AML), as has been demonstrated in studies by the major cooperative groups in the United States and Europe. Still, despite high-intensity chemotherapy and bone marrow transplantation, only about half of the children diagnosed with AML are cured. Future improvements are unlikely to come from further increases in chemotherapy intensity. Alternative approaches, such as risk-directed therapy based on different prognostic criteria; differentiation therapy with all-trans-retinoic acid (ATRA, Vesanoid), arsenic trioxide (Trisenox), or azacytidine; and immunotherapy with monoclonal antibodies, tumor vaccines, or cytokines may lead to further advances.